Answers are grounded in this paper and cite their sources.
Introduction: Daratumumab (DARA) is a human IgGκ monoclonal antibody that targets CD38 with a direct on-tumor and immunomodulatory mechanism of action. DARA is approved across multiple lines of therapy for patients with multiple myeloma. In the primary analysis of the phase 3 ALCYONE study (median follow-up, 16.5 months), a significant progression-free survival (PFS) benefit was achieved with D-VMP versus VMP alone (median not reached vs 18.1 months; hazard ratio [HR], 0.50; 95% confidence interval [CI], 0.38-0.65; P <0.001) in transplant-ineligible patients with NDMM, with no increase in overall toxicity (Mateos MV, N Engl J Med 2018). With longer follow-up (median follow-up, 40.1 months), D-VMP significantly prolonged overall survival (OS) compared to VMP alone (median not reached in either arm; HR, 0.60; 95% CI, 0.46-0.80; P = 0.0003). The rate of minimal residual disease (MRD) negativity was also higher with D-VMP versus VMP (28% versus 7%; P <0.0001; Mateos MV, Lancet 2020). Here, we present an updated analysis of ALCYONE after a median follow-up of 74.7 months. Methods: Patients with NDMM ineligible for high-dose chemotherapy and autologous stem cell transplant were randomized 1:1 to receive VMP ± DARA. Randomization was stratified by International Staging System disease stage (I vs II vs III), region (Europe vs other), and age (<75 vs ≥75 years). All patients received up to nine 6-week cycles of VMP (V: 1.3 mg/m2 SC on Days 1, 4, 8, 11, 22, 25, 29, and 32 of Cycle 1 and Days 1, 8, 22, and 29 of Cycles 2-9; M: 9 mg/m2 PO on Days 1-4 of Cycles 1-9; P: 60 mg/m2 PO on Days 1-4 of Cycles 1-9) ± DARA (16 mg/kg IV given once weekly in Cycle 1, once every 3 weeks in Cycles 2-9, and once every 4 weeks in Cycles 10+ until disease progression). OS, MRD-negativity rate (10-5 sensitivity: clonoSEQ® version 2.0), and safety were secondary endpoints. Results: In total, 706 patients were randomized (D-VMP, n = 350; VMP, n = 356). Baseline characteristics were well balanced between treatment arms. After a median follow-up of 74.7 months, a 37% reduction in the risk of death was observed with D-VMP versus VMP; median OS was 82.7 months with D-VMP versus 53.6 months with VMP (HR, 0.63; 95% CI, 0.51-0.78; P <0.0001). The estimated 72-month OS rate was 55.8% with D-VMP versus 39.2% with VMP (Figure A). The observed OS benefit of D-VMP versus VMP alone was generally consistent across pre-specified patient subgroups (Figure B). The MRD-negativity rate was higher for D-VMP versus VMP (28.3% vs 7.0%; P <0.0001), as was the rate of sustained MRD negativity lasting ≥12 months (14.0% vs 2.8%; P <0.0001). The most common (occurring in ≥30% of patients in either arm) any grade treatment-emergent adverse events (TEAEs; D-VMP/VMP) were neutropenia (50.6%/52.5%), thrombocytopenia (50.0%/53.7%), anemia (32.4%/37.0%), upper respiratory tract infection (30.9%/14.1%), and peripheral sensory neuropathy (28.9%/34.5%). Grade 3/4 TEAEs occurred in 82.9% of D-VMP patients and 77.4% of VMP patients, with the most common (occurring in ≥15% of patients in either arm) being neutropenia (D-VMP/VMP; 40.2%/39.0%), thrombocytopenia (34.7%/37.9%), anemia (18.2%/19.8%), and pneumonia (15.6%/4.5%). Grade 3/4 infection rates were 29.8%/15.0%. Conclusions: In this updated analysis of ALCYONE, the addition of DARA to VMP continued to prolong OS versus VMP alone in transplant-ineligible patients with NDMM; median OS was reached in both arms for the first time after a median follow-up of >6 years. D-VMP also achieved a 4-fold higher MRD-negativity rate and a 5-fold higher ≥12-month sustained MRD-negativity rate versus VMP alone. No new safety concerns were observed with longer follow-up. Our results continue to support the use of D-VMP in transplant-ineligible patients with NDMM. Updated OS results based on extended follow-up will be presented at the meeting.
No takes yet. Share an insight, caveat, or question.
Mateos et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: